Migraine with Aura

Overview

Migraine with aura (MwA) is a subtype of migraine headache characterized by reversible neurological disturbances—called an “aura”—that precede or accompany the pain. The aura typically lasts 5‑60 minutes and may involve visual, sensory, language, or motor symptoms. MwA accounts for roughly 25‑30% of all migraine cases worldwide.

Who is affected? Migraine is three times more common in women than men, and MwA follows the same pattern. The disorder usually begins in adolescence or early adulthood, with peak prevalence between ages 20‑40. According to the World Health Organization (WHO), migraines affect about 1‑2 % of the global population, meaning roughly 15‑20 million people in the United States experience migraine, and an estimated 3‑4 million have the aura variant.^WHO

Symptoms

The hallmark of MwA is the aura, but the full symptom picture often evolves in stages.

1. Aura Phase (5‑60 minutes)

• Visual disturbances – scintillating lights, zig‑zag lines (fortification spectra), blind spots, or temporary loss of vision.
• Sensory aura – tingling or “pins‑and‑needles” sensations starting in the hand and spreading up the arm to the face.
• Language (aphasic) aura – difficulty finding words, speaking slurred, or understanding speech.
• Motor aura – weakness or paralysis on one side of the body (rare, termed hemiplegic migraine).
• Brainstem aura – vertigo, double vision, ataxia, or hearing changes without visual symptoms.

2. Headache Phase (4‑72 hours)

• Pulsating or throbbing pain, usually unilateral (one side of the head).
• Moderate to severe intensity; aggravated by routine physical activity.
• Nausea, vomiting, or abdominal discomfort.
• Photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

3. Post‑drome Phase (hours to a day)

• Fatigue, difficulty concentrating, mood changes, and a feeling of “mental fog.”

Note: Not all individuals experience every symptom, and aura can sometimes occur without a subsequent headache (silent migraine).

Causes and Risk Factors

The exact pathophysiology of MwA remains incompletely understood, but several mechanisms are implicated.

Pathophysiology

• Cortical spreading depression (CSD) – a wave of neuronal depolarization that spreads across the cortex, thought to trigger visual and sensory aura.^NIH
• Trigeminovascular system activation – leads to release of vasoactive peptides (e.g., CGRP) causing vasodilation and pain.
• Genetic predisposition – several migraine-associated genes (e.g., *CACNA1A*, *ATP1A2*) are more common in those with aura.

Risk Factors

• Female sex (hormonal fluctuations, especially estrogen changes).
• Family history of migraine or aura.
• Age 10‑45 (onset typically before 35).
• Triggers:
  • Hormonal: menstrual cycle, oral contraceptives.
  • Environmental: bright/flashing lights, strong odors, loud noises.
  • Dietary: caffeine overuse, alcohol (especially red wine), aged cheese, MSG, aspartame.
  • Sleep disturbances: irregular sleep patterns, sleep deprivation.
  • Stress and emotional tension.
• Comorbid conditions: depression, anxiety, cardiovascular disease, stroke risk (particularly in women >45 with aura).^{Mayo Clinic}

Diagnosis

Diagnosis is clinical, based on history and symptom pattern, but certain tests are used to rule out other conditions.

Step‑by‑step approach

1. Detailed History – onset, frequency, aura characteristics, triggers, family history.
2. Physical & Neurological Examination – usually normal between attacks.
3. Headache Diary – records date, time, aura features, meds, triggers; helps differentiate from other disorders.

Imaging & Laboratory Tests

• Magnetic Resonance Imaging (MRI) or CT scan – ordered when atypical features exist (e.g., sudden onset, progressive neurological deficits) to exclude tumor, hemorrhage, or ischemic stroke.
• Magnetic Resonance Angiography (MRA) – if arterial disease suspected.
• Blood work – only if systemic illness is suspected (e.g., anemia, infection).

Diagnostic Criteria (ICHD‑3)

The International Classification of Headache Disorders, 3rd edition (ICHD‑3), defines MwA as at least two attacks fulfilling:

• Aura lasting 5‑60 minutes, with fully reversible symptoms.
• At least one of: visual, sensory, speech/language, motor, or brainstem aura.
• Headache begins during aura or within 60 minutes after aura ends.

Treatment Options

Treatment is divided into acute (abortive) therapy for attacks and preventive therapy to reduce frequency.

Acute Medications

• Triptans (e.g., sumatriptan, rizatriptan) – 5‑HT1B/1D agonists, most effective if taken early. Contraindicated in patients with certain cardiovascular disease.
• NSAIDs – ibuprofen, naproxen; useful for mild‑moderate attacks or in combination with triptans.
• Anti‑emetics – metoclopramide or ondansetron for nausea.
• CGRP receptor antagonists (gepant class, e.g., ubrogepant) – newer option for patients who cannot take triptans.
• Ergots (e.g., dihydroergotamine) – reserved for refractory cases.

Preventive (Prophylactic) Medications

Typically considered when migraine days >4 per month, severe disability, or contraindication to acute meds.

• Beta‑blockers – propranolol, metoprolol.
• Antidepressants – amitriptyline, venlafaxine.
• Anticonvulsants – topiramate, valproate.
• CGRP monoclonal antibodies – erenumab, fremanezumab, galcanezumab; administered monthly or quarterly.
• OnabotulinumtoxinA – FDA‑approved for chronic migraine (≥15 headache days/month).

Procedural Options

• Occipital Nerve Stimulation – for refractory chronic migraine.
• Transcranial Magnetic Stimulation (TMS) – single‑pulse TMS can abort migraine with aura when used within the aura phase, per FDA clearance.

Lifestyle & Non‑pharmacologic Strategies

• Identify and avoid personal triggers (keep a diary).
• Regular sleep schedule – 7‑9 hours/night.
• Hydration – ≈2 L water daily.
• Balanced diet; limit caffeine to <200 mg/day.
• Regular aerobic exercise (e.g., brisk walking 30 min most days).
• Stress‑reduction techniques: mindfulness, biofeedback, yoga.
• Protective eyewear in bright environments.

Living with Migraine with Aura

Effective self‑management can dramatically improve quality of life.

• Headache Diary – record aura onset, duration, triggers, medication timing, and response.
• Medication Management – set reminders, avoid overuse (limit triptans/NSAIDs to ≤10 days/month to prevent medication‑overuse headache).
• Workplace Accommodations – request flexible lighting, quiet rooms, or the ability to rest during an aura.
• Family & Social Support – educate loved ones about aura signs so they can provide assistance (e.g., help a person who is experiencing visual loss.
• Emergency Planning – always carry a rescue medication and a note describing aura symptoms for emergency staff.

Prevention

Prevention blends medical and lifestyle measures.

Pharmacologic Prevention

• Start low and titrate up under physician supervision.
• Consider CGRP monoclonal antibodies for patients with ≥4 migraine days/month despite conventional prophylaxis.

Non‑pharmacologic Prevention

• Trigger Avoidance – use sunglasses, limit screen glare, wear earplugs in noisy settings.
• Regular Meal Timing – avoid skipping meals; low‑glycemic snacks can stabilize blood sugar.
• Exercise – moderate aerobic activity improves vascular tone and reduces frequency.
• Sleep Hygiene – maintain consistent bedtime/wake time; limit screens before bed.
• Stress Management – cognitive‑behavioral therapy (CBT) has strong evidence for reducing migraine frequency.^{Cleveland Clinic}

Complications

If left untreated or poorly controlled, MwA can lead to:

• Chronic migraine – progression to ≥15 headache days/month.
• Medication‑overuse headache – from frequent acute drug use.
• Increased cardiovascular risk – especially in women >45 with aura (higher odds of ischemic stroke and myocardial infarction).^CDC
• Psychiatric comorbidities – depression, anxiety, and reduced work productivity.
• Physical injury – due to sudden visual loss or vertigo during aura (e.g., falls).

When to Seek Emergency Care

---

**References**

1. World Health Organization. Headache disorders: a public health priority. 2022. Link
2. Mayo Clinic. Migraine with aura. 2023. Link
3. National Institutes of Health. Cortical spreading depression and migraine. 2021. Link
4. Cleveland Clinic. Migraine prevention. 2024. Link
5. Centers for Disease Control and Prevention. Stroke risk factors. 2023. Link